Palbociclib, ribociclib or abemaciclib

RT0466

Hi, trying to decide which of these to go for: Palbociclib, ribociclib or abemaciclib. Which is better for mean survival compared with standard anti-hormone therapy? Which drug has the safest profile with least side-effects and what does it actually guarantee in terms of life extension.

Facts, figures and experiences are welcome.

Thank you.

Moderators

Hi RT0466, and welcome to our community

Here are some pages from our site that you may find helpful:

Ibrance, Kisqali Verzenio.

And go here to find research news on these three as well: https://www.breastcancer.org/research-news/targete...

You may want to use the Search box to the left in the blue bar to find topics on these as well.

Also from our site:

About Ibrance, Kisqali, and Verzenio

Ibrance, Kisqali, and Verzenio are cyclin-dependent kinase 4/6 inhibitors, commonly called CDK4/6 inhibitors. A kinase is a type of protein in the body that helps control cell division. CDK4/6 inhibitors work by stopping cancer cells from dividing and growing.

Ibrance, Kisqali, and Verzenio are used in combination with a type of hormonal therapy called an aromatase inhibitor as the first hormonal therapy to treat advanced-stage or metastatic, hormone-receptor-positive, HER2-negative breast cancer in postmenopausal women. Arimidex (chemical name: anastrozole), Aromasin (chemical name: exemestane), and Femara (chemical name: letrozole) are aromatase inhibitors.

Ibrance, Kisqali, and Verzenio also are used in combination with the hormonal therapy Faslodex (chemical name: fulvestrant) to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that has grown while being treated with a different hormonal therapy, in postmenopausal women.

Ibrance also may be used to treat men diagnosed with advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer.

Kisqali also may be used to treat premenopausal and perimenopausal women. Premenopausal and perimenopausal women treated with Kisqali also should be treated with a luteinizing hormone-releasing hormone agonist, such as Zoladex (chemical name: goserelin), to suppress ovarian function.

Verzenio also may be used alone to treat men or women diagnosed with hormone-receptor-positive, HER2-negative metastatic or advanced-stage breast cancer if the cancer has grown after hormonal therapy treatment and earlier chemotherapy for metastatic disease.

All three CDK4/6 inhibitors are pills taken by mouth.

RT0466

Thank you moderators. I will do all the reading I can. But I was wondering what experiences people have had with these drugs (particularly perimenopausal women on zoladex and letrazole).

Lolis197138

Hi RT,

Hope you are well.

I have been almost 2 years on Kisqali and letrozole. I am taking Zaladex as well on a monthly basis. the first couple of months were a bit hard (hot flashes, moodiness, and sore joints and hair thinning) then my body adjusted and the tumor shrinked after 3 month on Kisqali. I have been stable since then and the side effects have subsided.

it is definitely worth a trial.

good luck with your choice.